Wednesday, 12 September 2012

Isotrex Gel (Stiefel Laboratories (UK) Limited)





1. Name Of The Medicinal Product



Isotrex Gel


2. Qualitative And Quantitative Composition



Isotretinoin 0.05% w/w



For excipients, see 6.1.



3. Pharmaceutical Form



Gel for topical application



4. Clinical Particulars



4.1 Therapeutic Indications



Isotrex Gel is intended for use in the treatment of mild to moderate inflammatory and non-flammatory acne vulgaris.



4.2 Posology And Method Of Administration



Apply Isotrex Gel sparingly over the whole affected area once or twice daily.



Patients should be advised that 6-8 weeks of treatment may be required before a therapeutic effect is observed.



The safety and efficacy of Isotrex Gel has not been established in children since acne vulgaris rarely presents in this age group.



There are no specific recommendations for use in the elderly. Acne vulgaris does not present in the elderly.



4.3 Contraindications



Isotrex Gel should not be used in patients with known hypersensitivity to any of the ingredients.



4.4 Special Warnings And Precautions For Use



Contact with the mouth, eyes and mucous membranes and with abraded or eczematous skin should be avoided. Care should be taken not to let the medication accumulate in skin fold areas and in the angles of the nose.



Application to sensitive areas of skin, such as the neck, should be made with caution.



Although tretinoin has not been shown to initiate or promote carcinogenesis in humans, tretinoin applied topically to albino hairless mice had resulted in a dose-related acceleration in ultraviolet-B radiation induced cutaneous tumours. The same author also observed the opposite effect in another study of low, non-irritating concentrations of tretinoin. The significance of these findings as related to man is unknown; however, caution should be observed in patients with a personal or family history of cutaneous epithelioma. Exposure to sunlight of areas treated with Isotrex Gel should be avoided or minimised. When exposure to strong sunlight cannot be avoided a sunscreen product and protective clothing should be used. Patients with sunburn should not use Isotrex Gel due to the possibility of increased sensitivity to sunlight. The use of sunlamps should be avoided during treatment.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Concomitant topical medication should be used with caution during therapy with Isotrex Gel. Particular caution should be exercised when using preparations containing a peeling agent (for example Benzoyl Peroxide) or abrasive cleansers.



4.6 Pregnancy And Lactation



Category B1.



There is inadequate evidence of the safety of topically applied isotretinoin in human pregnancy.



Isotretinoin has been associated with teratogenicity in humans when administered systemically. Reproduction studies conducted in rabbits using Isotrex Gel applied topically at up to 60 times the human dose have, however, revealed no harm to the foetus. The use of Isotrex gel should be avoided during pregnancy.



Use during lactation



Percutaneous absorption of isotretinoin from Isotrex Gel is negligible. It is not known, however, whether isotretinoin is excreted in human milk. Isotrex Gel should not be used during lactation.



4.7 Effects On Ability To Drive And Use Machines



Not applicable; the product is a topical preparation which acts locally at the site of application.



4.8 Undesirable Effects



In normal use, Isotrex Gel may cause stinging, burning or irritation; erythema and peeling at the site of application may occur.



If undue irritation occurs, treatment should be interrupted temporarily and resumed once the reaction subsides. If irritation persists, treatment should be discontinued. Reactions will normally resolve on discontinuation of therapy.



4.9 Overdose



Acute overdosage of Isotrex Gel has not been reported to date. Accidental ingestion of Isotrex Gel resulting in overdosage of isotretinoin could be expected to induce symptoms of hypervitaminosis A. These include severe headaches, nausea or vomiting, drowsiness, irritability and pruritus.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Isotretinoin is structurally and pharmacologically related to Vitamin A which regulates epithelial cell growth and differentiation.



The pharmacological action of isotretinoin remains to be fully elucidated. When used systemically it suppresses sebaceous gland activity and reduces sebum production; it also affects comedogenesis, suppresses Propionibacterium acnes and reduces inflammation.



When applied topically, the mode of action of isotretinoin may be comparable with its stereoisomer, tretinoin. Tretinoin stimulates mitosis in the epidermis and reduces intercellular cohesion in the stratum corneum; it contests the hyperkeratosis characteristic of acne vulgaris and aids desquamation, preventing the formation of lesions. Tretinoin also mediates an increased production of less cohesive epidermal sebaceous cells, this appears to promote the initial expulsion and subsequent prevention of comedones.



5.2 Pharmacokinetic Properties



Percutaneous absorption of isotretinoin from the gel is negligible. After applying 30g per day of isotretinoin 0.05% gel to acne of the face, chest and back for 30 days, HPLC assays for isotretinoin and tretinoin demonstrated non-detectable levels in the plasma samples (0.02μg/ml). Applying 14C isotretinoin in a cream base on the healthy skin of human volunteers resulted in only 0.03% of the topically applied dose being recovered through estimating the radioactivity of blood, urine and faecal samples



5.3 Preclinical Safety Data



Not applicable. The relevant information is given in Section 4.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Butylated Hydroxytoluene



Hydroxypropylcellulose



Ethanol



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



a) For the product as packaged for sale



3 years



b) After first opening the container



Two months



6.4 Special Precautions For Storage



Store below 25°C



6.5 Nature And Contents Of Container



Aluminium tube of 5g, 15g, 25g, 30g, 50g, 60g fitted with a screw cap.



6.6 Special Precautions For Disposal And Other Handling



There are no special instructions for use or handling of Isotrex Gel.



7. Marketing Authorisation Holder



GlaxoSmithKline UK Limited



980 Great West Road



Brentford



Middlesex



TW8 9GS



Trading as Stiefel



Stockley Park West



Uxbridge



Middlesex



UB11 1BT



8. Marketing Authorisation Number(S)



PL 19494/0063



9. Date Of First Authorisation/Renewal Of The Authorisation



20/12/2005



10. Date Of Revision Of The Text



14 December 2010




No comments:

Post a Comment